JP7465868B2 - 新規化合物 - Google Patents
新規化合物 Download PDFInfo
- Publication number
- JP7465868B2 JP7465868B2 JP2021521058A JP2021521058A JP7465868B2 JP 7465868 B2 JP7465868 B2 JP 7465868B2 JP 2021521058 A JP2021521058 A JP 2021521058A JP 2021521058 A JP2021521058 A JP 2021521058A JP 7465868 B2 JP7465868 B2 JP 7465868B2
- Authority
- JP
- Japan
- Prior art keywords
- benzofuran
- dione
- imidazolidine
- disorders
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18200626 | 2018-10-16 | ||
| EP18200626.2 | 2018-10-16 | ||
| PCT/GB2019/052937 WO2020079422A1 (en) | 2018-10-16 | 2019-10-16 | Novel compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022505143A JP2022505143A (ja) | 2022-01-14 |
| JP2022505143A5 JP2022505143A5 (enExample) | 2022-10-25 |
| JP7465868B2 true JP7465868B2 (ja) | 2024-04-11 |
Family
ID=63878368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521058A Active JP7465868B2 (ja) | 2018-10-16 | 2019-10-16 | 新規化合物 |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP3867247B1 (enExample) |
| JP (1) | JP7465868B2 (enExample) |
| KR (1) | KR102854594B1 (enExample) |
| AR (1) | AR116713A1 (enExample) |
| AU (1) | AU2019360017B9 (enExample) |
| BR (1) | BR112021006940A2 (enExample) |
| DK (1) | DK3867247T3 (enExample) |
| ES (1) | ES2988842T3 (enExample) |
| FI (1) | FI3867247T3 (enExample) |
| HR (1) | HRP20241318T1 (enExample) |
| HU (1) | HUE068686T2 (enExample) |
| IL (1) | IL282096B2 (enExample) |
| LT (1) | LT3867247T (enExample) |
| MX (1) | MX2021004386A (enExample) |
| PL (1) | PL3867247T3 (enExample) |
| PT (1) | PT3867247T (enExample) |
| SI (1) | SI3867247T1 (enExample) |
| TW (1) | TWI827706B (enExample) |
| WO (1) | WO2020079422A1 (enExample) |
| ZA (1) | ZA202101487B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12358901B2 (en) | 2018-10-16 | 2025-07-15 | Autifony Therapeutics Limited | KV3 modulators |
| JP7522203B2 (ja) * | 2020-02-06 | 2024-07-24 | アウトイフオンイ トヘラペウトイクス リミテッド | Ｋｖ３モジュレーター |
| CA3228446A1 (en) | 2021-08-09 | 2023-02-16 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators for use in autism spectrum disorders |
| US20240327406A1 (en) | 2021-08-10 | 2024-10-03 | Autifony Therapeutics Limited | Potassium channel modulators |
| EP4630117A1 (en) | 2022-12-06 | 2025-10-15 | Autifony Therapeutics Limited | Compounds for the treatment of centra nervous system disorders |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012076877A1 (en) | 2010-12-06 | 2012-06-14 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| WO2013083994A1 (en) | 2011-12-06 | 2013-06-13 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| WO2013182851A1 (en) | 2012-06-06 | 2013-12-12 | Autifony Therapeutics Limited | Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required |
| WO2017103604A1 (en) | 2015-12-16 | 2017-06-22 | Autifony Therapeutics Limited | Hydantoin modulators of kv3 channels |
| WO2018109484A1 (en) | 2016-12-16 | 2018-06-21 | Autifony Therapeutics Limited | Hydantoin modulators of kv3 channels |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5788404B2 (ja) | 2009-12-11 | 2015-09-30 | アウトイフオンイ トヘラペウトイクス リミテッド | イミダゾリジンジオン誘導体 |
| US9193704B2 (en) | 2011-06-07 | 2015-11-24 | Autifony Therapeutics Limited | Hydantoin derivatives as KV3 inhibitors |
| GB201209986D0 (en) | 2012-06-06 | 2012-07-18 | Autifony Therapeutics Ltd | Novel compounds |
| EP2852588B8 (en) | 2012-05-22 | 2018-01-10 | Autifony Therapeutics Limited | Hydantoin derivatives as kv3 inhibitors |
| US9422252B2 (en) | 2012-05-22 | 2016-08-23 | Autifony Therapeutics Limited | Triazoles as Kv3 inhibitors |
| GB201521751D0 (en) | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201613163D0 (en) | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
-
2019
- 2019-10-16 TW TW108137290A patent/TWI827706B/zh active
- 2019-10-16 ES ES19790048T patent/ES2988842T3/es active Active
- 2019-10-16 HR HRP20241318TT patent/HRP20241318T1/hr unknown
- 2019-10-16 BR BR112021006940-2A patent/BR112021006940A2/pt unknown
- 2019-10-16 PL PL19790048.3T patent/PL3867247T3/pl unknown
- 2019-10-16 PT PT197900483T patent/PT3867247T/pt unknown
- 2019-10-16 IL IL282096A patent/IL282096B2/en unknown
- 2019-10-16 WO PCT/GB2019/052937 patent/WO2020079422A1/en not_active Ceased
- 2019-10-16 HU HUE19790048A patent/HUE068686T2/hu unknown
- 2019-10-16 DK DK19790048.3T patent/DK3867247T3/da active
- 2019-10-16 SI SI201930828T patent/SI3867247T1/sl unknown
- 2019-10-16 MX MX2021004386A patent/MX2021004386A/es unknown
- 2019-10-16 FI FIEP19790048.3T patent/FI3867247T3/fi active
- 2019-10-16 KR KR1020217014348A patent/KR102854594B1/ko active Active
- 2019-10-16 EP EP19790048.3A patent/EP3867247B1/en active Active
- 2019-10-16 AR ARP190102939A patent/AR116713A1/es unknown
- 2019-10-16 JP JP2021521058A patent/JP7465868B2/ja active Active
- 2019-10-16 LT LTEPPCT/GB2019/052937T patent/LT3867247T/lt unknown
- 2019-10-16 AU AU2019360017A patent/AU2019360017B9/en active Active
-
2021
- 2021-03-04 ZA ZA2021/01487A patent/ZA202101487B/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012076877A1 (en) | 2010-12-06 | 2012-06-14 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| WO2013083994A1 (en) | 2011-12-06 | 2013-06-13 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| WO2013182851A1 (en) | 2012-06-06 | 2013-12-12 | Autifony Therapeutics Limited | Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required |
| WO2017103604A1 (en) | 2015-12-16 | 2017-06-22 | Autifony Therapeutics Limited | Hydantoin modulators of kv3 channels |
| WO2018109484A1 (en) | 2016-12-16 | 2018-06-21 | Autifony Therapeutics Limited | Hydantoin modulators of kv3 channels |
Non-Patent Citations (1)
| Title |
|---|
| WANG, C. et al.，Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978)，Journal of Medicinal Chemistry，2016年，59(23)，pp. 10705-10718 |
Also Published As
| Publication number | Publication date |
|---|---|
| DK3867247T3 (da) | 2024-09-16 |
| AU2019360017A1 (en) | 2021-04-01 |
| ZA202101487B (en) | 2024-05-30 |
| PT3867247T (pt) | 2024-09-17 |
| AR116713A1 (es) | 2021-06-02 |
| KR20210076081A (ko) | 2021-06-23 |
| EP3867247B1 (en) | 2024-07-24 |
| FI3867247T3 (fi) | 2024-10-30 |
| IL282096B2 (en) | 2024-07-01 |
| TW202035394A (zh) | 2020-10-01 |
| HRP20241318T1 (hr) | 2024-12-20 |
| AU2019360017B9 (en) | 2025-03-27 |
| IL282096A (en) | 2021-05-31 |
| PL3867247T3 (pl) | 2024-12-09 |
| JP2022505143A (ja) | 2022-01-14 |
| IL282096B1 (en) | 2024-03-01 |
| HUE068686T2 (hu) | 2025-01-28 |
| AU2019360017B2 (en) | 2025-03-06 |
| EP3867247A1 (en) | 2021-08-25 |
| SI3867247T1 (sl) | 2024-11-29 |
| TWI827706B (zh) | 2024-01-01 |
| MX2021004386A (es) | 2021-06-04 |
| BR112021006940A2 (pt) | 2021-07-13 |
| ES2988842T3 (es) | 2024-11-21 |
| KR102854594B1 (ko) | 2025-09-02 |
| WO2020079422A1 (en) | 2020-04-23 |
| LT3867247T (lt) | 2024-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7465868B2 (ja) | 新規化合物 | |
| CN103596943B (zh) | 用作kv3抑制剂的乙内酰脲衍生物 | |
| JP7036725B2 (ja) | Ｋｖ３チャネルのヒダントインモジュレーター | |
| CA2856654C (en) | Hydantoin derivatives useful as kv3 inhibitors | |
| WO2018109484A1 (en) | Hydantoin modulators of kv3 channels | |
| WO2013182850A1 (en) | Isobenzofuran- 5 -yl-oxy- (hetero) aryl - imidazolidine - 2, 4 -dione derivatives modulators of kv3 potassium channels for the treatment of cns disorders. | |
| JP7522203B2 (ja) | Ｋｖ３モジュレーター | |
| KR20240046748A (ko) | 칼륨 채널 조절제 | |
| RU2830279C2 (ru) | Новые соединения | |
| US12358901B2 (en) | KV3 modulators | |
| HK40059039B (en) | Novel compounds | |
| HK40059039A (en) | Novel compounds | |
| EA049235B1 (ru) | Модуляторы kv3 | |
| CA3169057C (en) | Kv3 modulators | |
| HK40081003B (zh) | Kv3调节剂 | |
| HK40081003A (en) | Kv3 modulators | |
| HK40108089A (zh) | 钾通道调节剂 | |
| BR112014013400B1 (pt) | Compostos derivados de hidantoína úteis como inibidores de kv3 e seus usos na profilaxia ou tratamento de distúrbios auditivos e esquizofrenia ou no tratamento de síndrome do x frágil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221014 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221014 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231005 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231024 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240122 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240312 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240401 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7465868 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |